CLINICAL TRIAL: TREATMENT OPTIONS FOR TYPE 2 DIABETES IN ADOLESCENTS AND YOUTH (

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 TODAY试验是一项比较性试验，主要目的是在入组的10 - 17岁T2 DM患者中，基于血糖控制，比较三个治疗组在至治疗失败时间方面的疗效。 试验将包括三个组。 三个治疗组比较为：（1）二甲双胍单药与二甲双胍+强化生活方式方案，（2）二甲双胍单药与二甲双胍+罗格列酮，（3）二甲双胍+强化生活方式方案与二甲双胍+罗格列酮。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The TODAY trial is a comparative experiment with the primary objective to compare the efficacy of three treatment arms on time to treatment failure based upon glycemic control in patients enrolled from 10 to 17 years in age with T2DM. The trial will be comprised of three arms. The three treatment group comparisons are: (1) metformin alone versus metformin plus intensive lifestyle program, (2) metformin alone versus metformin plus rosiglitazone, and (3) metformin plus intensive lifestyle program versus metformin plus rosiglitazone.